Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation

W. D. Haire, L. C. Stephens, G. D. Kotulak, E. I. Ruby, Bruce Geoffrey Gordon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antithrombin is a naturally-occurring anticoagulant protein. Congenital deficiency of this protein predisposes to thrombotic complications. Acquired deficiency of antithrombin occurs in a variety of clinical circumstances, including hematopoietic stem cell transplantation (HSCT), and is associated with multiorgan failure and death in these situations. Normalization of antithrombin levels by infusion of concentrates of this protein has been found to be beneficial in many of these situations, but has not been routinely used in HSCT. Before antithrombin concentrates can be widely recommended in HSCT, its pharmacokinetics at various phases of the transplant process must be defined to allow estimation of the proper dose and dosing interval. To this end, the recovery and half-life of antithrombin concentrate was determined prior to and 7, 14 and 28 days after beginning the preparative regimen in nine patients with lymphoma undergoing HSCT. The recovery of the infused material was constant during the transplant hospitalization, averaging 2.0% per unit/kg. The half-life, however, dropped significantly during the latter half of the transplant procedure. The half-lives pre-chemotherapy and on day 7 were similar and averaged 20.4 h. On days 14 and 21 the half-lives were significantly lower at 12.2 and 15.5 h, respectively. The drop in half-life during the transplant process will require antithrombin concentrate to be given more frequently during this time to maintain constant antithrombin levels.

Original languageEnglish (US)
Pages (from-to)505-507
Number of pages3
JournalBone marrow transplantation
Volume15
Issue number4
StatePublished - Jan 1 1995

Fingerprint

Antithrombins
Hematopoietic Stem Cell Transplantation
Pharmacokinetics
Transplants
Half-Life
Protein Deficiency
Anticoagulants
Lymphoma
Proteins
Hospitalization
Drug Therapy

Keywords

  • Antithrombin
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation. / Haire, W. D.; Stephens, L. C.; Kotulak, G. D.; Ruby, E. I.; Gordon, Bruce Geoffrey.

In: Bone marrow transplantation, Vol. 15, No. 4, 01.01.1995, p. 505-507.

Research output: Contribution to journalArticle

Haire, W. D. ; Stephens, L. C. ; Kotulak, G. D. ; Ruby, E. I. ; Gordon, Bruce Geoffrey. / Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation. In: Bone marrow transplantation. 1995 ; Vol. 15, No. 4. pp. 505-507.
@article{e4779b812a5843e7afa5b2f5228ef891,
title = "Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation",
abstract = "Antithrombin is a naturally-occurring anticoagulant protein. Congenital deficiency of this protein predisposes to thrombotic complications. Acquired deficiency of antithrombin occurs in a variety of clinical circumstances, including hematopoietic stem cell transplantation (HSCT), and is associated with multiorgan failure and death in these situations. Normalization of antithrombin levels by infusion of concentrates of this protein has been found to be beneficial in many of these situations, but has not been routinely used in HSCT. Before antithrombin concentrates can be widely recommended in HSCT, its pharmacokinetics at various phases of the transplant process must be defined to allow estimation of the proper dose and dosing interval. To this end, the recovery and half-life of antithrombin concentrate was determined prior to and 7, 14 and 28 days after beginning the preparative regimen in nine patients with lymphoma undergoing HSCT. The recovery of the infused material was constant during the transplant hospitalization, averaging 2.0{\%} per unit/kg. The half-life, however, dropped significantly during the latter half of the transplant procedure. The half-lives pre-chemotherapy and on day 7 were similar and averaged 20.4 h. On days 14 and 21 the half-lives were significantly lower at 12.2 and 15.5 h, respectively. The drop in half-life during the transplant process will require antithrombin concentrate to be given more frequently during this time to maintain constant antithrombin levels.",
keywords = "Antithrombin, Stem cell transplantation",
author = "Haire, {W. D.} and Stephens, {L. C.} and Kotulak, {G. D.} and Ruby, {E. I.} and Gordon, {Bruce Geoffrey}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "15",
pages = "505--507",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation

AU - Haire, W. D.

AU - Stephens, L. C.

AU - Kotulak, G. D.

AU - Ruby, E. I.

AU - Gordon, Bruce Geoffrey

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Antithrombin is a naturally-occurring anticoagulant protein. Congenital deficiency of this protein predisposes to thrombotic complications. Acquired deficiency of antithrombin occurs in a variety of clinical circumstances, including hematopoietic stem cell transplantation (HSCT), and is associated with multiorgan failure and death in these situations. Normalization of antithrombin levels by infusion of concentrates of this protein has been found to be beneficial in many of these situations, but has not been routinely used in HSCT. Before antithrombin concentrates can be widely recommended in HSCT, its pharmacokinetics at various phases of the transplant process must be defined to allow estimation of the proper dose and dosing interval. To this end, the recovery and half-life of antithrombin concentrate was determined prior to and 7, 14 and 28 days after beginning the preparative regimen in nine patients with lymphoma undergoing HSCT. The recovery of the infused material was constant during the transplant hospitalization, averaging 2.0% per unit/kg. The half-life, however, dropped significantly during the latter half of the transplant procedure. The half-lives pre-chemotherapy and on day 7 were similar and averaged 20.4 h. On days 14 and 21 the half-lives were significantly lower at 12.2 and 15.5 h, respectively. The drop in half-life during the transplant process will require antithrombin concentrate to be given more frequently during this time to maintain constant antithrombin levels.

AB - Antithrombin is a naturally-occurring anticoagulant protein. Congenital deficiency of this protein predisposes to thrombotic complications. Acquired deficiency of antithrombin occurs in a variety of clinical circumstances, including hematopoietic stem cell transplantation (HSCT), and is associated with multiorgan failure and death in these situations. Normalization of antithrombin levels by infusion of concentrates of this protein has been found to be beneficial in many of these situations, but has not been routinely used in HSCT. Before antithrombin concentrates can be widely recommended in HSCT, its pharmacokinetics at various phases of the transplant process must be defined to allow estimation of the proper dose and dosing interval. To this end, the recovery and half-life of antithrombin concentrate was determined prior to and 7, 14 and 28 days after beginning the preparative regimen in nine patients with lymphoma undergoing HSCT. The recovery of the infused material was constant during the transplant hospitalization, averaging 2.0% per unit/kg. The half-life, however, dropped significantly during the latter half of the transplant procedure. The half-lives pre-chemotherapy and on day 7 were similar and averaged 20.4 h. On days 14 and 21 the half-lives were significantly lower at 12.2 and 15.5 h, respectively. The drop in half-life during the transplant process will require antithrombin concentrate to be given more frequently during this time to maintain constant antithrombin levels.

KW - Antithrombin

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0029045511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029045511&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 505

EP - 507

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -